Lisa S Kahalley1, M Douglas Ris2, David R Grosshans2, M Fatih Okcu2, Arnold C Paulino2, Murali Chintagumpala2, Bartlett D Moore2, Danielle Guffey2, Charles G Minard2, Heather H Stancel2, Anita Mahajan2. 1. Lisa S. Kahalley, M. Douglas Ris, M. Fatih Okcu, Murali Chintagumpala, Danielle Guffey, Charles G. Minard, and Heather H. Stancel, Baylor College of Medicine, Houston; and David R. Grosshans, Arnold C. Paulino, Bartlett D. Moore, and Anita Mahajan, The University of Texas MD Anderson Cancer Center, Houston, TX. kahalley@bcm.edu. 2. Lisa S. Kahalley, M. Douglas Ris, M. Fatih Okcu, Murali Chintagumpala, Danielle Guffey, Charles G. Minard, and Heather H. Stancel, Baylor College of Medicine, Houston; and David R. Grosshans, Arnold C. Paulino, Bartlett D. Moore, and Anita Mahajan, The University of Texas MD Anderson Cancer Center, Houston, TX.
Abstract
PURPOSE: Compared with photon radiation (XRT), proton beam radiation therapy (PBRT) reduces dose to normal tissues, which may lead to better neurocognitive outcomes. We compared change in intelligence quotient (IQ) over time in pediatric patients with brain tumors treated with PBRT versus XRT. PATIENTS AND METHODS: IQ scores were available for 150 patients (60 had received XRT, 90 had received PBRT). Linear mixed models examined change in IQ over time since radiation therapy (RT) by RT group, controlling for demographic/clinical characteristics. Craniospinal and focal RT subgroups were also examined. RESULTS: In the PBRT group, no change in IQ over time was identified (P = .130), whereas in the XRT group, IQ declined by 1.1 points per year (P = .004). IQ slopes did not differ between groups (P = .509). IQ was lower in the XRT group (by 8.7 points) versus the PBRT group (P = .011). In the craniospinal subgroup, IQ remained stable in both the PBRT (P = .203) and XRT groups (P = .060), and IQ slopes did not differ (P = .890). IQ was lower in the XRT group (by 12.5 points) versus the PBRT group (P = .004). In the focal subgroup, IQ scores remained stable in the PBRT group (P = .401) but declined significantly in the XRT group by 1.57 points per year (P = .026). IQ slopes did not differ between groups (P = .342). CONCLUSION: PBRT was not associated with IQ decline or impairment, yet IQ slopes did not differ between the PBRT and XRT groups. It remains unclear if PBRT results in clinically meaningful cognitive sparing that significantly exceeds that of modern XRT protocols. Additional long-term data are needed to fully understand the neurocognitive impact of PBRT in survivors of pediatric brain tumors.
PURPOSE: Compared with photon radiation (XRT), proton beam radiation therapy (PBRT) reduces dose to normal tissues, which may lead to better neurocognitive outcomes. We compared change in intelligence quotient (IQ) over time in pediatric patients with brain tumors treated with PBRT versus XRT. PATIENTS AND METHODS: IQ scores were available for 150 patients (60 had received XRT, 90 had received PBRT). Linear mixed models examined change in IQ over time since radiation therapy (RT) by RT group, controlling for demographic/clinical characteristics. Craniospinal and focal RT subgroups were also examined. RESULTS: In the PBRT group, no change in IQ over time was identified (P = .130), whereas in the XRT group, IQ declined by 1.1 points per year (P = .004). IQ slopes did not differ between groups (P = .509). IQ was lower in the XRT group (by 8.7 points) versus the PBRT group (P = .011). In the craniospinal subgroup, IQ remained stable in both the PBRT (P = .203) and XRT groups (P = .060), and IQ slopes did not differ (P = .890). IQ was lower in the XRT group (by 12.5 points) versus the PBRT group (P = .004). In the focal subgroup, IQ scores remained stable in the PBRT group (P = .401) but declined significantly in the XRT group by 1.57 points per year (P = .026). IQ slopes did not differ between groups (P = .342). CONCLUSION: PBRT was not associated with IQ decline or impairment, yet IQ slopes did not differ between the PBRT and XRT groups. It remains unclear if PBRT results in clinically meaningful cognitive sparing that significantly exceeds that of modern XRT protocols. Additional long-term data are needed to fully understand the neurocognitive impact of PBRT in survivors of pediatric brain tumors.
Authors: S L Palmer; O Goloubeva; W E Reddick; J O Glass; A Gajjar; L Kun; T E Merchant; R K Mulhern Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: Shawna L Palmer; Amar Gajjar; Wilburn E Reddick; John O Glass; Larry E Kun; Shengjie Wu; Xiaoping Xiong; Raymond K Mulhern Journal: Neuropsychology Date: 2003-10 Impact factor: 3.295
Authors: Benjamin A Greenberger; Margaret B Pulsifer; David H Ebb; Shannon M MacDonald; Robin M Jones; William E Butler; Mary S Huang; Karen J Marcus; Jennifer A Oberg; Nancy J Tarbell; Torunn I Yock Journal: Int J Radiat Oncol Biol Phys Date: 2014-07-08 Impact factor: 7.038
Authors: Iska Moxon-Emre; Eric Bouffet; Michael D Taylor; Normand Laperriere; Nadia Scantlebury; Nicole Law; Brenda J Spiegler; David Malkin; Laura Janzen; Donald Mabbott Journal: J Clin Oncol Date: 2014-02-10 Impact factor: 44.544
Authors: Lisa S Kahalley; Rachel Peterson; M Douglas Ris; Laura Janzen; M Fatih Okcu; David R Grosshans; Vijay Ramaswamy; Arnold C Paulino; David Hodgson; Anita Mahajan; Derek S Tsang; Normand Laperriere; William E Whitehead; Robert C Dauser; Michael D Taylor; Heather M Conklin; Murali Chintagumpala; Eric Bouffet; Donald Mabbott Journal: J Clin Oncol Date: 2019-11-27 Impact factor: 44.544